Bausch Health Companies Inc. (BHC) – Reported organic growth across all the segments

in on June 11, 2019

Bausch Health is off to a strong start in 2019 with the continued growth of XIFAXAN® which grew 11% in the quarter, the launch of BRYHALI™, the successful acquisition of TRULANCE®, and the approval of DUOBRII™ and expected a launch in June.

Number of Pages – 47

Contents

Executive Summary

Financial Statements

–Income Statement and Forecast

–Balance Sheet

–Cash Flow

–Q1FY19 – Results Overview

–Q4FY18 & FY18 – Results Overview

–Segment Performance

–Q1FY19 – Business Updates

–FY19 Guidance

–Conclusion

–GAAP to Non-GAAP Reconciliation

Historical Performance

–Key Ratios

–Profitability Ratios, Asset Turnover Ratio, Growth Ratio

–Per Share Items and Key ratios

–Key Balance Sheet and Cash Flow Items

–P/E Band

Product Performance and Key Developments

–Ownership

–Competition

–Key Developments

Valuation and Consensus Performance

–Relative Valuation

–Analyst Recommendations

Market Price Performance

CrispIdea Coverage Chart

Release Information

  • Released
    :

    June 11, 2019

  • Last Updated
    :

    June 27, 2019